Samuel GW OW

Dr. Samuel GW OW

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
Bee Luan KhooBee Luan Khoo
Bee Luan Khoo
SLSoo Chin Lee
Soo Chin Lee
PKPrashant Kumar
Prashant Kumar
TTTuan Zea Tan
Tuan Zea Tan
MWMajid Ebrahimi Warkiani
Majid Ebrahimi Warkiani
JTJEAN PAUL THIERY
JEAN PAUL THIERY
Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy

1 September 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SLSoo-Chin Lee
Soo-Chin Lee
NSNoriko Shimasaki
Noriko Shimasaki
JLJoline S.J. Lim
Joline S.J. Lim
AWAndrea Wong
Andrea Wong
KYKritika Yadav
Kritika Yadav
DCDario Campana
Dario Campana
Purpose: Natural killer (NK) cells exert antibody-dependent cell cytotoxicity (ADCC). We infused expanded, activated autologous NK cells to potentiate trastuzumab-mediated ADCC in patients with HER2-positive malignancies. Patients and Methods: In a phase I trial, patients with treatment-refractory HER2-positive solid tumors received trastuzumab, with or without bevacizumab, and autologous NK cells expanded by 10-day coculture with K562-mb15-41BBL cells. Primary objectives included safety and recommended phase II dose determination; secondary objectives included monitoring NK-cell activity and RECIST antitumor efficacy. Results: In 60 cultures with cells from 31 subjects, median NK-cell expansion from peripheral blood was 340-fold (range, 91–603). NK cells expressed high levels of CD16, the mediator of ADCC, and exerted powerful killing of trastuzumab-targeted cells. In the 22 subjects enrolled in phase I dose escalation, trastuzumab plus NK cells were well tolerated; MTD was not reached. Phase IB (n = 9) included multiple cycles of NK cells (1 × 107/kg) and addition of bevacizumab. Although no objective response was observed, 6 of 19 subjects who received at least 1 × 107/kg NK cells at cycle 1 had stable disease for ≥6 months (median, 8.8 months; range 6.0–12.0). One patient, the only one with the high-affinity F158V CD16 variant, had a partial response. Peripheral blood NK cells progressively downregulated CD16 postinfusion; paired tumor biopsies showed increased NK cells, lymphocytic infiltrates, and apoptosis posttreatment. Conclusions: NK-cell therapy in combination with trastuzumab was well tolerated, with target engagement and preliminary antitumor activity, supporting continued assessment of this approach in phase II trials.

10 January 2017 in Frontiers in Oncology
Verified
Journal Article
Open access
RSRaghav Sundar
Raghav Sundar
ABAishwarya Bandla
Aishwarya Bandla
STStacey Sze Hui Tan
Stacey Sze Hui Tan
Lun-De LiaoLun-De Liao
Lun-De Liao
NKNesaretnam Barr Kumarakulasinghe
Nesaretnam Barr Kumarakulasinghe
EWEinar P. V. Wilder-Smith
Einar P. V. Wilder-Smith
Background Peripheral neuropathy (PN) due to paclitaxel is a common dose-limiting toxicity with no effective prevention or treatment. We hypothesize that continuous-flow limb hypothermia can reduce paclitaxel-induced PN. Patients and methods An internally controlled pilot trial was conducted to investigate the neuroprotective effect of continuous-flow limb hypothermia in breast cancer patients receiving weekly paclitaxel. Patients underwent limb hypothermia of one limb for a duration of 3 hours with every paclitaxel infusion, with the contralateral limb used as control. PN was primarily assessed using nerve conduction studies (NCS) before the start of chemotherapy, and after one, three and six months. Skin temperature and tolerability to hypothermia was monitored using validated scores. Results Twenty patients underwent a total of 218 cycles of continuous-flow limb hypothermia at a coolant temperature of 22°C. Continuous-flow limb hypothermia achieved mean skin temperature reduction of 1.5 ± 0.7°C and was well tolerated, with no premature termination of cooling due to intolerance. Grade 3 PN occurred in 2 patients (10%), grade 2 in 2 (10%), and grade 1 in 12 (60%). Significant correlation was observed between amount of skin cooling and motor nerve amplitude preservation at six months (p < 0.0005). Sensory velocity and amplitude in the cooled limbs were less preserved than in the control limbs but the difference did not attain statistical significance. One patient with a history of diabetes mellitus had significant preservation of compound muscle action potential in the cooled limb on NCS analysis. Conclusion This study suggests that continuous limb hypothermia accompanying paclitaxel infusion may reduce paclitaxel-induced PN and have therapeutic potential in select patients and warrants further investigation. The method is safe and well tolerated.

1 July 2020 in Annals of Oncology
Verified
Journal Article
Closed access
NNN. Ngoi
N. Ngoi
JLJ. Lim
J. Lim
SOSamuel GW OW
Samuel GW OW
WJW. Y. Jen
W. Y. Jen
MLM. Lee
M. Lee
AJA. D. Jeyasekharan
A. D. Jeyasekharan

17 July 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
GCGloria H.J. Chan
Gloria H.J. Chan
POPei Yi Ong
Pei Yi Ong
JLJeffrey J.H. Low
Jeffrey J.H. Low
HKHwai Loong Kong
Hwai Loong Kong
SOSamuel GW OW
Samuel GW OW
SLSoo-Chin Lee
Soo-Chin Lee
Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers

1 September 2020 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
JCJack Chan
Jack Chan
YSYirong Sim
Yirong Sim
SOSamuel GW OW
Samuel GW OW
JLJoline Si Jing Lim
Joline Si Jing Lim
GKGrace Kusumawidjaja
Grace Kusumawidjaja
TTTira Jing Ying Tan
Tira Jing Ying Tan
The ensuing COVID-19 pandemic poses unprecedented and daunting challenges to the routine delivery of oncological and supportive care to patients with breast cancer. Considerations include the infective risk of patients who are inherently immunosuppressed from their malignancy and therapies, long-term oncological outcomes from the treatment decisions undertaken during this extraordinary period, and diverted healthcare resources to support a coordinated whole-of-society outbreak response. In this review, we chronicle the repercussions of the COVID-19 outbreak on breast cancer management in Singapore and describe our approach to triaging and prioritising care of breast tumours. We further propose adaptations to established clinical processes and practices across the different specialties involved in breast oncology, with references to the relevant evidence base or expert consensus guidelines. These recommendations have been developed within the unique context of Singapore’s public healthcare sector. They can serve as a resource to guide breast cancer management for future contingencies in this city-state, while certain elements therein may be extrapolatable to other medical systems during this global public health emergency.